Last reviewed · How we verify
Birch pollen allergoid — Competitive Intelligence Brief
phase 3
Allergen immunotherapy (allergoid)
Birch pollen allergens (Bet v 1 and related epitopes)
Immunology / Allergy
Biologic
Live · refreshed every 30 min
Target snapshot
Birch pollen allergoid (Birch pollen allergoid) — Allergopharma GmbH & Co. KG. Birch pollen allergoid is a modified birch pollen extract that induces immune tolerance to birch pollen allergens through gradual desensitization.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Birch pollen allergoid TARGET | Birch pollen allergoid | Allergopharma GmbH & Co. KG | phase 3 | Allergen immunotherapy (allergoid) | Birch pollen allergens (Bet v 1 and related epitopes) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Allergen immunotherapy (allergoid) class)
- Allergopharma GmbH & Co. KG · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Birch pollen allergoid CI watch — RSS
- Birch pollen allergoid CI watch — Atom
- Birch pollen allergoid CI watch — JSON
- Birch pollen allergoid alone — RSS
- Whole Allergen immunotherapy (allergoid) class — RSS
Cite this brief
Drug Landscape (2026). Birch pollen allergoid — Competitive Intelligence Brief. https://druglandscape.com/ci/birch-pollen-allergoid. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab